Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type A

Seven types (A–G) of botulinum neurotoxin (BoNT) target peripheral cholinergic neurons where they selectively proteolyze SNAP-25 (BoNT/A, BoNT/C1, and BoNT/E), syntaxin1 (BoNT/C1), and synaptobrevin (BoNT/B, BoNT/D, BoNT/F, and BoNT/G), SNARE proteins responsible for transmitter release, to cause neuromuscular paralysis but of different durations. BoNT/A paralysis lasts longest (4–6 months) in humans, hence its widespread clinical use for the treatment of dystonias. Molecular mechanisms underlying these distinct inhibitory patterns were deciphered in rat cerebellar neurons by quantifying the half-life of the effect of each toxin, the speed of replenishment of their substrates, and the degradation of the cleaved products, experiments not readily feasible at motor nerve endings. Correlation of target cleavage with blockade of transmitter release yielded half-lives of inhibition for BoNT/A, BoNT/C1, BoNT/B, BoNT/F, and BoNT/E (≫31, ≫25, ∼10, ∼2, and ∼0.8 days, respectively), equivalent to the neuromuscular paralysis times found in mice, with recovery of release coinciding with reappearance of the intact SNAREs. A limiting factor for the short neuroparalytic durations of BoNT/F and BoNT/E is the replenishment of synaptobrevin or SNAP-25, whereas pulse labeling revealed that extended inhibition by BoNT/A, BoNT/B, or BoNT/C1 results from longevity of each protease. These novel findings could aid development of new toxin therapies for patients resistant to BoNT/A and effective treatments for human botulism.

• Publication year

  2003

• Venue

  Journal of Biological Chemistry

• Publication date

  2003-01-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1074/JBC.M209821200PMID 12381720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Processing of tetanus and botulinum A neurotoxins in isolated chromaffin cells

  2004cited by this paper
• Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type A

  2003cited by this paper
• Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

  2002cited by this paper
• Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

  2002cited by this paper
• Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis.

  2001cited by this paper
• Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.

  2001cited by this paper
• A Late Phase of Exocytosis from Synaptosomes Induced by Elevated [Ca2+]i Is Not Blocked by Clostridial Neurotoxins

  2000cited by this paper
• Neurotoxins affecting neuroexocytosis.

  2000cited by this paper
• Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.

  1999cited by this paper
• A single amino acid near the C terminus of the synaptosomeassociated protein of 25 kDa (SNAP-25) is essential for exocytosis in chromaffin cells.

  1999cited by this paper
• Persistence of botulinum neurotoxin action in cultured spinal cord cells 1,2

  1999cited by this paper
• Protein Kinase B Stimulates the Translocation of GLUT4 but Not GLUT1 or Transferrin Receptors in 3T3-L1 Adipocytes by a Pathway Involving SNAP-23, Synaptobrevin-2, and/or Cellubrevin*

  1999cited by this paper
• Rescue of Exocytosis in Botulinum Toxin A-poisoned Chromaffin Cells by Expression of Cleavage-resistant SNAP-25

  1999cited by this paper
• Retention of cleaved synaptosome-associated protein of 25 kDa (SNAP-25) in neuromuscular junctions: a new hypothesis to explain persistence of botulinum A poisoning.

  1999cited by this paper
• Truncated SNAP-25 (1-197), like botulinum neurotoxin A, can inhibit insulin secretion from HIT-T15 insulinoma cells.

  1998cited by this paper
• Syntaxin and 25‐kDa synaptosomal‐associated protein: Differential effects of botulinum neurotoxins C1 and A on neuronal survival

  1998cited by this paper
• Differential turnover of syntaxin and SNAP‐25 during synaptogenesis in cultured cerebellar granule neurons

  1998cited by this paper
• Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans.

  1998cited by this paper
• Clinical spectrum of botulism

  1998cited by this paper
• Botulinum neurotoxin B inhibits insulin-stimulated glucose uptake into 3T3-L1 adipocytes and cleaves cellubrevin unlike type A toxin which failed to proteolyze the SNAP-23 present.

  1997cited by this paper
• Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human.

  1997cited by this paper
• Human response to botulinum toxin injection: Type B compared with type A

  1997cited by this paper
• Importance of two adjacent C-terminal sequences of SNAP-25 in exocytosis from intact and permeabilized chromaffin cells revealed by inhibition with botulinum neurotoxins A and E.

  1997cited by this paper
• Synaptic Vesicle Recycling in Cultured Cerebellar Granule Cells: Role of Vesicular Acidification and Refilling

  1997cited by this paper
• Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology

  1997cited by this paper
• Productive and non‐productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain

  1996cited by this paper
• Distinct exocytotic responses of intact and permeabilised chromaffin cells after cleavage of the 25-kDa synaptosomal-associated protein (SNAP-25) or synaptobrevin by botulinum toxin A or B.

  1996cited by this paper
• Identification of a Novel Syntaxin- and Synaptobrevin/VAMP-binding Protein, SNAP-23, Expressed in Non-neuronal Tissues*

  1996cited by this paper
• Neural cell culture: a practical approach

  1995cited by this paper
• Blockade by botulinum neurotoxin B of catecholamine release from adrenochromaffin cells correlates with its cleavage of synaptobrevin and a homologue present on the granules.

  1995cited by this paper
• Clostridial neurotoxins compromise the stability of a low energy SNARE complex mediating NSF activation of synaptic vesicle fusion.

  1995cited by this paper
• Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly.

  1994cited by this paper
• The syntaxin family of vesicular transport receptors.

  1993cited by this paper
• A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion.

  1993cited by this paper
• Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin

  1992cited by this paper
• Serum and depolarizing agents cause acute neurotoxicity in cultured cerebellar granule cells: role of the glutamate receptor responsive to N-methyl-D-aspartate.

  1990cited by this paper
• The identification of a novel synaptosomal-associated protein, SNAP-25, differentially expressed by neuronal subpopulations

  1989cited by this paper
• Synaptobrevin: an integral membrane protein of 18,000 daltons present in small synaptic vesicles of rat brain.

  1989cited by this paper
• Endogenous Amino Acid Release from Cultured Cerebellar Neuronal Cells: Effect of Tetanus Toxin on Glutamate Release

  1989cited by this paper
• VAMP-1: a synaptic vesicle-associated integral membrane protein.

  1988cited by this paper
• The role of depolarization in the survival and differentiation of cerebellar granule cells in culture

  1987cited by this paper
• Tetanus Toxin in Dissociated Spinal Cord Cultures: Long‐Term Characterization of Form and Action

  1986cited by this paper
• Survival, morphology and adhesion properties of cerebellar interneurones cultured in chemically defined and serum-supplemented medium.

  1985cited by this paper
• Striatonigral and pallidonigral pathways studied by a combination of retrograde horseradish peroxidase tracing and a pharmacohistochemical method for gamma-aminobutyric acid transaminase.

  1985cited by this paper
• Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization

  1984cited by this paper
• Observations on rat cerebellar cells in vitro: influence of substratum, potassium concentration and relationship between neurones and astrocytes.

  1983cited by this paper
• Selective release of glutamate from cerebellar granule cells differentiating in culture.

  1982cited by this paper

• Phosphorylation of SNAP-25 at Ser187 is enhanced following its cleavage by Botulinum Neurotoxin Serotype A, promoting the dominant-negative effect of the resulting fragment

  2025cites this paper
• Botulinum toxin in focus: evolution, pharmacology, and its expanding clinical impact

  2025cites this paper
• A Retrospective Case Series Study of Illegal Cosmetic Iatrogenic Botulism: Outbreak Analysis and Response Lessons.

  2025cites this paper
• Bifunctional Inhibition of Botulinum Neurotoxin A Protease: Unexpected Active Site Inhibition Enhances Covalent Targeting of an Allosteric Site.

  2025cites this paper
• Evaluation of a Cell-Based Potency Assay for Detection of the Potency of TrenibotulinumtoxinE® (TrenibotE)

  2025cites this paper
• Inter-Domain interactions Slow BoNT/A's onset of action.

  2025cites this paper
• Scoping Review: The Effects of Interrupted Onabotulinumtoxin A Treatment for Chronic Migraine Prevention During the COVID-19 Pandemic

  2024cites this paper
• Update on Non-Interchangeability of Botulinum Neurotoxin Products

  2024influential citation
• Long-term safety and efficacy of MBA-P01 for the treatment of glabellar lines: results from a multicenter, repeated-dose, open-label extension study

  2024cites this paper
• Treating neuropathic pain and comorbid affective disorders: Preclinical and clinical evidence

  2024cites this paper
• The Degradation of Botulinum Neurotoxin Light Chains Using PROTACs

  2024cites this paper
• Expression, purification and application of a recombinant, membrane permeating version of the light chain of botulinum toxin B

  2024cites this paper
• A Validation of the Equivalence of the Cell-Based Potency Assay Method with a Mouse LD50 Bioassay for the Potency Testing of OnabotulinumtoxinA

  2024cites this paper
• Tirbanibulin (KX2‐391) analog KX2‐361 inhibits botulinum neurotoxin serotype A mediated SNAP‐25 cleavage in pre‐ and post‐intoxication models in cells

  2024cites this paper
• Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications

  2024cites this paper
• Rivastigmine ameliorates botulinum-induced hippocampal damage and spatial memory impairment in male rats.

  2023cites this paper
• Aminopyridines Restore Ventilation and Reverse Respiratory Acidosis at Late Stages of Botulism in Mice

  2023cites this paper
• Distribution of Cleaved SNAP-25 in the Rat Brain, following Unilateral Injection of Botulinum Neurotoxin-A into the Striatum

  2023cites this paper
• Action of Botulinum Neurotoxin E Type in Experimental Epilepsies

  2023cites this paper
• Use of botulinum toxin in aesthetic medicine and gynaecology: current approaches, controversies, and future directions

  2023cites this paper
• Characterization of Serotype CD Mosaic Botulinum Neurotoxin in Comparison with Serotype C and A

  2023cites this paper
• Neuromuscular recovery from botulism involves multiple forms of compensatory plasticity

  2023cites this paper
• Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2

  2023cites this paper
• The Multispecialty Toxin: A Literature Review of Botulinum Toxin

  2022cites this paper
• Administration of botulinum toxin a and vascular endhotelial growth factor reduce norepinephrine levels and increase viability of modified mcfarlane flap in wistar rat

  2022influential citation
• Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine

  2022cites this paper
• The Pharmacology of Botulinum Toxin Type A

  2022cites this paper
• Botulinum toxin type E: A review

  2022influential citation
• Botulinum Injection into the Proximal Intestinal Wall of Diet-induced Obese Mice Leads to Weight Loss and Improves Glucose and Fat Tolerance.

  2022cites this paper
• Critical analysis in the advancement of cell-based assays for botulinum neurotoxin

  2022cites this paper
• Neuronal delivery of antibodies has therapeutic effects in animal models of botulism

  2021cites this paper
• Development of Two-Dimensional Nanomaterials Based Electrochemical Biosensors on Enhancing the Analysis of Food Toxicants

  2021cites this paper
• Delivery of single-domain antibodies into neurons using a chimeric toxin–based platform is therapeutic in mouse models of botulism

  2021cites this paper
• Irreversible inhibition of BoNT/A protease: proximity-driven reactivity contingent upon a bifunctional approach.

  2021cites this paper
• Controversial issues of pharmacology of botulinum toxin type A

  2021cites this paper
• COVALENT INHIBITION OF BOTULINUM NEUROTOXIN A - EXPLORATION OF WARHEAD REACTIVITY AND FUNCTION USING A BIFUNCTIONAL APPROACH.

  2021cites this paper
• Use of Crystallography and Molecular Modeling for the Inhibition of the Botulinum Neurotoxin A Protease.

  2021cites this paper
• Clostridial Neurotoxins: Structure, Function and Implications to Other Bacterial Toxins

  2021cites this paper
• Exploring treatments for drooling in children with neurological disorders

  2020cites this paper
• Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development

  2020cites this paper
• Infant botulism.

  2020cites this paper
• Neurotoxine botulique : mécanismes moléculaires et cellulaires de son action sur le système nerveux

  2020cites this paper
• Can Botulinum Toxin A Play a Role in Treatment of Chronic Pelvic Pain Syndrome in Female Patients?—Clinical and Animal Evidence

  2020cites this paper
• Efficacy and Safety of a New Botulinum Toxin (HU-014) Versus Existing Onabotulinumtoxin A in Subjects With Moderate to Severe Glabellar Lines.

  2020cites this paper
• Safety and Clinical Outcomes of an Equine-Derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States.

  2020cites this paper
• Neurobiology and therapeutic applications of neurotoxins targeting transmitter release.

  2019cites this paper
• The Structure and Classification of Botulinum Toxins.

  2019cites this paper
• Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.

  2019cites this paper
• The effects of Botox injection into the masseter in the mandibular condyle are not transient

  2019cites this paper
• The effects on the mandibular condyle of Botox injection into the masseter are not transient.

  2019cites this paper
• Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons

  2019cites this paper
• [Foodborne botulism - a re-emerging public health challenge].

  2019cites this paper
• Effect of Perivascular Injection of Botulinum Toxin Type A versus Lidocaine in Survival of Random Pattern Flaps in a Rat Model

  2019cites this paper
• Botulinum and Tetanus Neurotoxins.

  2019cites this paper
• Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport®).

  2019cites this paper
• Co-Expression Network Approach to Studying the Effects of Botulinum Neurotoxin-A

  2018cites this paper
• Light Chain Diversity among the Botulinum Neurotoxins

  2018cites this paper
• Botulinum neurotoxin formulations: overcoming the confusion

  2018cites this paper
• Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice

  2018cites this paper
• Management of oral secretions in neurological disease

  2018cites this paper
• Therapeutic Approaches of Botulinum Toxin in Gynecology

  2018cites this paper
• A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo

  2018cites this paper
• The in vitro detection of botulinum neurotoxin-cleaved endogenous VAMP is epitope-dependent.

  2018cites this paper
• Title :A review of the longevity of effect of Botulinum Toxin in wrinkle treatments.

  2018cites this paper
• Control of neurotransmission by diffusional properties of a presynaptic plasma membrane protein - syntaxin1A

  2018cites this paper
• A review of the longevity of effect of botulinum toxin in wrinkle treatments

  2018cites this paper
• Neuronal selectivity of botulinum neurotoxins.

  2018cites this paper
• Clinical outcomes of Botox injections for chronic temporomandibular disorders: do we understand how Botox works on muscle, pain, and the brain?

  2017cites this paper
• A Cell Line for Detection of Botulinum Neurotoxin Type B

  2017influential citation
• Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques

  2017cites this paper
• Botulinum Neurotoxin: A Multifunctional Protein for the Development of New Therapeutics

  2017cites this paper
• Clostridium botulinum and the Most Poisonous Poison

  2017cites this paper
• Treatment of Genito-Pelvic Pain/Penetration Disorder

  2017cites this paper
• Design of modified botulinum neurotoxin A1 variants with a shorter persistence of paralysis and duration of action

  2017cites this paper
• Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology

  2017influential citation
• BoNT/AB hybrid maintains similar duration of paresis as BoNT/A wild‐type in murine running wheel assay

  2017cites this paper
• Uptake of Clostridial Neurotoxins into Cells and Dissemination.

  2017cites this paper
• Management of oral secretions in neurological disease

  2017cites this paper
• Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication

  2017cites this paper
• Botulinum Toxin: From Molecule to Medicine

  2017cites this paper
• Relevance of Intrinsic Disorder in Protein Structure and Function

  2016cites this paper
• Septins: Regulators of Protein Stability

  2016cites this paper
• Colorimetric detection of active botulinum neurotoxin using Cu2+ mediated gold nanoparticles agglomeration

  2016cites this paper
• Creating recombinant fusion protein conjugates for targeting SNARE protease into neuroendocrine cells

  2016influential citation
• Botulinum and Tetanus Neurotoxin-Induced Blockade of Synaptic Transmission in Networked Cultures of Human and Rodent Neurons.

  2016cites this paper
• Non‐cosmetic dermatological uses of botulinum neurotoxin

  2016cites this paper
• Tetanus and Botulinum Neurotoxins

  2016cites this paper
• Translocation and dissemination to target neurons of botulinum neurotoxin type B in the mouse intestinal wall

  2016cites this paper
• Effect of botulinum toxin a and nitroglycerin on random skin flap survival in rats

  2016cites this paper
• Diversity of Group I and II Clostridium botulinum Strains from France Including Recently Identified Subtypes

  2016cites this paper
• Protein Toxins in Modeling Biochemistry

  2016cites this paper
• Effect of botulinum toxin A and nitroglycerin on random skin flap survival in rats.

  2016cites this paper
• Engineering of botulinum neurotoxins as novel therapeutic tools

  2015cites this paper
• A reduced graphene oxide-Au based electrochemical biosensor for ultrasensitive detection of enzymatic activity of botulinum neurotoxin A

  2015cites this paper
• Current gaps in basic science knowledge of botulinum neurotoxin biological actions.

  2015cites this paper
• Botulinum Toxin: A Clinical Update on Ophthalmic Uses

  2015cites this paper
• Neuronal response in Alzheimer’s and Parkinson’s disease: the effect of toxic proteins on intracellular pathways

  2015cites this paper
• Clostridial neurotoxins: from the cellular and molecular mode of action to their therapeutic use

  2015cites this paper
• Is downer cow syndrome related to chronic botulism?

  2015cites this paper
• Pathogenesis of Clostridium botulinum in Humans

  2015cites this paper